Cognition Therapeutics (CGTX) H.C. Wainwright 26th Annual Global Investment Conference 2024 summary

Conference overview

• Over 600 companies presented across sectors including life sciences, fintech, technology, clean tech, and mining.

• Sessions included one-on-one meetings, corporate presentations, and live panels from September 9–11.

Clinical program highlights

• Lead asset CT-1812 targets amyloid beta oligomers, showing neuroprotective effects in Alzheimer's and other neurodegenerative diseases.

• SHINE trial in mild to moderate Alzheimer's showed 39% slowing of cognitive decline, with strong safety and tolerability.

• 100 mg dose performed as well or better than 300 mg, guiding future trial design.

• Biomarker NfL decreased in treated patients, supporting efficacy.

Pipeline and ongoing studies

• START trial enrolling 540 early AD patients for 18 months, including those on lecanemab for real-world combination data.

• SHIMMER trial in dementia with Lewy bodies (DLB) completed enrollment; data expected by year-end.

• MAGNIFY trial in dry AMD enrolling 246 adults for two years, aiming for first oral treatment in this indication.